补肾养肝方药对长期服用左旋多巴帕金森病大鼠黑质纹状体功能的影响

目的：探讨补肾养肝方药对长期服用左旋多巴帕金森病大鼠黑质纹状体系统功能的影响。方法：建立6－羟基多巴胺（6－OHDA）帕金森病大鼠模型，随机分为4组：假手术组、模型组、左旋多巴组、左旋多巴加补肾养肝组，每组10只。各组药物处理每日1次，12周后处死取材。结果：（1）模型组纹状体多巴胺（DA）、多巴克（DOPAC）、高香草酸（HVA）含量及DOPAC／DA、HVA／DA显著低于假手术组（P＜0．05），降低幅度约为90％；左旋多巴组DA、DOPAC、HVA含量及DOPAC／DA、HVA／DA明显高于假手术组；左旋多巴加补肾养肝组DA、DPOAC、HVA含量及DOPAC／DA、HVA／DA显著低于左旋多巴组（P＜0．05），接近假手术组水平（P＞0．05）。（2）模型组纹状体酪氨酸羟化酶（TH）活性显著低于假手术组，左旋多巴组较模型组显著降低，左旋多巴加补肾养肝组纹状体TH活性显著高于左旋多巴组（P＜0．05）。（3）左旋多巴加补肾养肝组中脑THmRNA表达明显高于左旋多巴组。结论：补肾养肝方药能有效改善长期服用左旋多巴造成的不良反应。

Effect of Bushen Yanggan Recipe on Nigrostriatal Function in Parkinsoni an Model Rats after Long-term Levodopa Treatment

To investigate the effect of Bushen Yanggan R ec ipe (BSYGR) on the function and morphology of nigrostriatal system in Parkinsoni an model rats with long term levodopa treatment. Methods: Unilateral Parkinsonian rat models were established b y injecting 6 hydroxydopamine (6 OHDA) into the substantia nigra pars compacta (SNpc) and ventral segmental area (VTA). Animals were randomly divided into four groups, the sham control group, model control group, levodopa group and levodop a plus BSYGR group. The content of striatal dopa (DA), digydroxy phenyl acetic acid (DOPAC) and homovanilic acid (HVA) or the THmRNA expression level in the mi dbrain were measured. Results: (1) Levels of striatal DA, DOPAC, HVA, DOPAC/DA, HVA/ DA decreased in the model control group by about 90% as compared with those in s ham control group (P<0 05). These parameters in the levodopa g roup were higher than those in the sham control group, while in the levodopa plu s BSYGR group, they were lower than those in the levodopa group (P< 0 01), approaching the levels in the sham control group (P>0 05). (2) Striatal TH activity in the model group was lower than that in the sham control group significantly, but higher than that in the levodopa group, while in the levodopa plus BSYGR group, it showed a level obviously higher than that i n the levodopa group (P<0 05). (3) Levodopa plus BSYGR group had a higher midbrain THmRNA expression level than that in the levodopa group. Conclusion: BSYGR could effectively reduce the side effects re sulting from the long term treatment of levodopa.